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Abstract
Background: Expression of various long noncoding RNAs (lncRNAs) may affect cancer prognosis. Here, we aim to
gather and examine all evidence on the potential role of lncRNAs as novel predictors of survival in human cancer.
Methods: We systematically searched through PubMed, to identify all published studies reporting on the association
between any individual lncRNA or group of lncRNAs with prognosis in human cancer (death or other clinical
outcomes). Where appropriate, we then performed quantitative synthesis of those results using meta-analytic
methods to identify the true effect size of lncRNAs on cancer prognosis. The reliability of those results was then
examined using measures of heterogeneity and testing for selective reporting biases.
Results: Three hundred ninety-two studies were screened to eventually identify 111 eligible studies on 127
datasets. In total, these represented 16,754 independent participants pertaining to 53 individual and 6 grouped
lncRNAs within a total of 19 cancer sites. Overall, 83 % of the studies we identified addressed overall survival and 32
% of the studies addressed recurrence-free survival. For overall survival, 96 % (88/92) of studies identified a statistically
significant association of lncRNA expression to prognosis. Meta-analysis of 6 out of 7 lncRNAs for which three or
more studies were available, identified statistically significant associations with overall survival. The lncRNA HOTAIR
was by far the most broadly studied lncRNA (n = 29; of 111 studies) and featured a summary hazard ratio (HR) of 2.22
(95 % confidence interval (CI), 1.86–2.65) with modest heterogeneity (I2 = 49 %; 95 % CI, 14–79 %). Prominent excess
significance was demonstrated across all meta-analyses (p-value = 0.0003), raising the possibility of substantial selective
reporting biases.
Conclusions: Multiple lncRNAs have been shown to be strongly associated with prognosis in diverse cancers, but
substantial bias cannot be excluded in this field and larger studies are needed to understand whether these prognostic
information may eventually be useful.
Keywords: LncRNA, Cancer, Cancer biomarkers, Prognosis, Survival analysis, Excess significance, Small-study effects,
Selective reporting biases
Background
Non-coding RNAs (ncRNAs) have been proposed in the
last decade as regulators of cancer pathways and bio-
markers of cancer outcomes [1–4]. Potentially inform-
ative biomarkers based on ncRNAs include microRNAs
(miRs) [5] and the larger long non-coding RNAs
(lncRNAs). NcRNAs were up to recently disregarded as
‘junk’ and despite constituting the large majority of
RNAs being transcribed, their role in normal develop-
ment and cellular physiology in health and disease is
only recently becoming apparent [2, 6, 7].
LncRNAs refer to any ncRNA consisting of more than
200 nucleotides. They are functionally heterogeneous
molecules [6, 8], themselves sub-classified into large
intergenic non-coding RNAs (lincRNA), transcribed
ultraconserved regions (T-UCRs) and many others [2].
Of an estimated putative 140,000 different ncRNAs in
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total [9], lncRNAs are estimated to constitute propor-
tionally the largest class, with the most comprehensive
approach to date confirming 58,648 expressed
lncRNAs [10]. Even though the function of lncRNAs is
still being debated [11], certain lncRNAs have been
implicated in functions related to regulation of gene
expression in health and disease [2, 6–8, 12–15].
Well-studied examples include the lncRNA Xist,
which initiates X-chromosome inactivation in female
cells by recruiting repressive complexes to the X-
chromosome under inactivation [16–18] and H19,
which has been shown to play a significant role in gen-
omic imprinting [19, 20].
Of particular interest however is, that it is now clear
that lncRNAs are major players in tumorigenesis [7–9,
21–23]. In this context, the most well studied lncRNA is
HOTAIR (HOmeobox (HOX) Transcript AntIsense
RNA), which has been shown to recruit the PRC2 (Poly-
comb Repressive Complex 2) complex and eventually
lead to epigenetic silencing of metastasis suppressor
genes [2, 24].
More than 20 meta-analyses studying the role of
lncRNAs in cancer prognosis have been published so
far, all within the past 2 years. All of these studied a sin-
gle lncRNA, either in relation to a specific cancer or to
any cancer. The two most studied lncRNAs are
MALAT1 and HOTAIR, which have been the subject of
10 and 7 meta-analyses respectively. The latest meta-
analysis on MALAT1 for all cancer types showed that
its upregulation is statistically significantly associated
with poor overall survival (pooled hazard ratio [HR],
2.14; 95 % CI, 1.74–2.64) with low between-study het-
erogeneity (I2, 4.3 %; p-value = 0.399), on the basis of 9
studies [25]. The results were similar to the latest meta-
analysis of HOTAIR (HR, 2.33; 95 % CI, 1.77–3.09), but
with significant between-study heterogeneity (Cochran’s
Q-test p-value = 0.016), on the basis of 16 studies [26].
Interestingly, all meta-analyses published so far have
been produced by Chinese groups and all identified a
statistically significant association of all lncRNAs stud-
ied to prognosis in cancer. However, no systematic re-
view and meta-analysis to-date has identified all
lncRNAs studied in the context of cancer and to what
extent these might be of prognostic significance.
In this paper, we aimed to examine the potential role
of all lncRNAs ever investigated in the context of can-
cer survival prediction, as novel predictors of survival
in human cancer. We utilized a field-wide meta-
analysis approach [27] to systematically identify and
examine all published papers trying to associate
lncRNAs to prognosis in human cancer, and to quanti-
tatively synthesize data directly related to prognosis




This report has been structured on the basis of
PRISMA [28].
Eligibility criteria
We considered published reports of a prospective or
retrospective study design that had explored the associ-
ation of any single or combination of stated lncRNAs to
any of the following types of survival analysis: disease-
specific survival (DSS, duration of time from the day of
diagnosis to the day of death due to cancer); metastasis-
free survival (MFS, duration of time from day of diagno-
sis to the day of diagnosing a metastatic event); overall/
cumulative survival (OS, duration of time from day of
diagnosis to the day of death due to any cause); progres-
sion/event/disease-free survival (PFS, duration of time
from day of first treatment to the day evidence of cancer
progression are identified or the patient dies of any
cause); and recurrence-free survival (RFS, duration of
time from day of cure from cancer to the day evidence
of cancer progression/recurrence is identified). Survival
analyses measuring different types of survival were
treated separately at all times. Studies describing the
association of individual or groups of lncRNAs with clin-
icopathologic variables (e.g. Stage, Grade, Distant metas-
tasis, etc.), without specifically examining associations to
any of the aforementioned survival analyses, were ex-
cluded. We likewise excluded cross-sectional studies and
studies concerning genetic alterations of an lncRNA (e.g.
polymorphisms or methylation patterns). Any kind of
quantitative lncRNA analysis (quantitative real time–
PCR, in situ hybridization) was eligible.
For meta-analysis eligibility, a study had to also pro-
vide the effect size and confidence interval for the asso-
ciation of an individual or group of lncRNAs with any of
the above survival outcomes, or report information
through which this effect size and confidence interval
could be calculated [29, 30]. Wherever the same cohort
had published more than one overlapping analysis, we
only used the most encompassing data (for example, the
classification of glioma would be preferred over glio-
blastoma multiforme). Two reviewers (S. Serghiou and
A. Kyriakopoulou) identified eligible studies, and any
contested articles were adjudicated by a third reviewer
(J. P. A. Ioannidis).
Information sources
We systematically searched PubMed (1950 to September,
2015) for studies of any language that analyzed associa-
tions between lncRNAs and prognosis in human cancer.
Our search strategy was developed in consideration of
previous recommendations [30] and used the clinical
queries prognosis filter, which has been reported to have
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an average estimated sensitivity of 92 % for detecting ar-
ticles related to prognosis [5, 31]. Our search term was:
(Prognosis/Broad [filter]) AND ((lncRNA OR “lnc RNA”
OR “long noncoding ribonucleic acid” OR “long noncod-
ing RNA” OR “long non-coding ribonucleic acid” OR
“long intergenic noncoding RNA” OR “long intergenic
non-coding RNA” OR “long non-coding RNA” OR “long
ncRNA” OR “lincRNA” OR “linc RNA”) AND (cancer
OR carcinoma OR tumor OR neoplas* OR tumour OR
malignan* OR metastat* OR metastas* OR leukemia OR
leukaemia OR lymphoma OR recurren* OR “lymph
node” OR response) AND (Humans[Mesh] AND Eng-
lish[lang])). The search was last updated to include arti-
cles published through September 26, 2015.
Study selection
We used the programming language R [32] to remove
duplicate records. Title and abstract were screened to
identify relevant articles. The full manuscript of the rele-
vant articles was screened against our eligibility criteria.
Any uncertainties were resolved by consensus with JPA.
Data were collected by two reviewers (SS, AK) and saved
in a pre-designed extraction form on Google Sheets.
Where information was ambiguous (such as, for ex-
ample, mentioning multiple types of lncRNA quantifica-
tion methods but not clarifying which one of those was
used to provide the quantities utilized in the survival
analysis), this was labelled as ‘unclear’. An attempt was
made to contact the authors when information was
clearly logically inconsistent, as in for example quoting a
hazard ratio (HR) outside the confidence interval (CI),
but none replied. In one paper, the lncRNA expression
level [33] was subdivided into low versus medium versus
high; for this paper we only extracted the comparison
between low versus high expression levels. The following
data were extracted for all articles following the
CHARMS checklist [34]: title; authors; year of publica-
tion; journal of publication; groupings (i.e. whether
lncRNAs were studied one by one or in groups); what
lncRNAs were studied; whether an agnostic approach to
identifying the studied lncRNAs was used (where an ag-
nostic approach would be one assuming no prior know-
ledge regarding the choice of lncRNA to be studied);
cancer site (e.g. brain) and cancer subtype (e.g. glioblast-
oma multiforme); whether a paper reported clinicopath-
ologic data of its sample and which ones; whether an
attempt of associating those clinicopathologic data to
lncRNAs was made and for which ones; whether an at-
tempt of associating clinicopathologic data to prognosis
was made and for which ones; whether an attempt was
made to explain the clinical outcomes using non-clinical
studies (in vivo, in vitro); the types of survival analyses
used (as above); type of study design (prospective cohort,
retrospective cohort, unreported); means of lncRNA
quantitative analysis (qRT–PCR, qPCR, in situ
hybridization (ISH), other); and whether the paper tried
to make any non-clinical associations of the identified
lncRNAs to cancer in vitro. For eligible articles we fur-
ther extracted: country and city of origin of the study
cohort, period of sample recruitment, range of sample
ages, mean/median age with confidence interval, the
population type (general population, non-general
population (e.g. veterans), unreported), stage of can-
cer upon initial patient presentation, sample size,
means of tissue preservation (frozen, paraffin-
embedded, both, other), any and what preoperative
treatment was given, the total number of lncRNAs
studied, the type of metric the paper used to
characterize their results (hazard ratio, relative risk,
odds ratio, p-value), type of analysis (i.e. univariable or
multivariable), lncRNA quantity cut-off and its unit
(i.e. the threshold based on which lncRNA expression
was deemed upregulated or downregulated by the
study), the sample size of each comparison group, the
minimum and maximum participant follow-up time,
the number of censored participants throughout follow-
up and whether this was explicitly stated or read off the
Kaplan-Meier curves, the HR and its CI (provided or
inferred, e.g. from p-values and HR point estimates), the
p-value and whether this was statistically significant at
p < 0.05 and whether an attempt to validate the reported
results was made, and if so, what type of validation
method was used (internal or external). For eligibility
for meta-analysis, enough information to extract or
calculate the natural logarithm of the hazard ratio and
its variance must have been provided.
Whenever multiple datasets were combined into a sin-
gle dataset to study a specific lncRNA, we only extracted
the summary HR, rather than extracting the HR respect-
ive to each constitutive dataset. If multiple datasets were
assessed within the same study without being combined
into a single dataset, we extracted the HR respective to
each dataset, as they represent separate estimates. Where
both the log-rank and Breslow tests were reported, only
the log-rank was extracted. No cohort was used more than
once and effect sizes describing a broader class of cancer
(e.g. glioma) were preferred over subclassifications of that
(e.g. glioblastoma multiforme). Three studies reported ef-
fect sizes that were excluded from further consideration
because the quoted HRs contradicted the text [35] or they
were either outside the CI or could not have possibly led
to the quoted CI [36, 37]; this led to complete exclusion of
two out of these three studies [35, 37]. Our database can
be freely accessed here: https://goo.gl/EjCDAp.
Risk of bias in individual studies
Risk of bias in individual studies was assessed on the basis
of the framework of assessing internal validity of articles
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dealing with prognosis [30, 38] and recommendations re-
garding reporting of biomarker studies [39, 40].
Meta-analysis
Summary measures and synthesis of results
We meta-analyzed data on lncRNAs for which three or
more estimates of their effect on a specific survival
outcome were available. Therefore, meta-analyses were
only done for OS and RFS. Effect sizes for OS and RFS
were meta-analyzed separately. Our principal summary
measure was the summary HR. Standard errors were
calculated using: ln (upper limit of CI/lower limit of
CI)/(2 × 1.96). Estimates were synthesized using a
random-effects model and estimated using the re-
stricted maximum-likelihood ratio method. As previ-
ously described [27], four meta-analyses were done for
each of: (1) multivariable data, (2) univariable data, (3)
multivariable data combined with univariable data
whenever multivariable data were unavailable (prefer-
entially multivariable) and (4) univariable data com-
bined with multivariable data whenever univariable
data were unavailable (preferentially univariable).
Given the similarity between the estimates of all four
types of meta-analysis and the importance of multivari-
able modelling in prognostic studies, this report only
quotes the estimates of the ‘preferentially multivari-
able’ meta-analysis; the rest can be found in Additional
file 1: Table S2. For each estimate we provide the effect
size and 95 % CI. Heterogeneity was analyzed using the
Q and I2 statistics and the 95 % CI of I2 was also calcu-
lated [41, 42]. These analyses were done using R and
the package metafor 1.9-8 [43]. Data were combined
for each type of lncRNA regardless of cancer type.
Wherever an lncRNA had been analyzed three or more
times for one or more specific cancer type, a post hoc
subgroup analysis per cancer type was done for that
lncRNA.
Risk of bias across studies
Risk of publication bias is a significant concern in
prognostic studies [30]. We explored excess signifi-
cance for factors reported by at least 3 studies [44].
Briefly, for every meta-analyzed risk factor we com-
pare the number of observed significant results (O) at
α = 0.05, to the number of expected significant results
(E), where E = sum of power of each study within a
specific meta-analysis. Power was calculated taking as
plausible effect for the risk factor the effect seen in
the most precise study (lowest standard error). The
difference between O and E was assessed using a two-
tailed binomial test, with α = 0.1, as previously sug-
gested [45]. O and E were also summed and compared
across all meta-analyses.
Results
Literature search and description of studies
We initially identified 397 records, from which 286 were
excluded (Fig. 1), leaving us with 111 studies eligible for
systematic review (Additional file 2), of which 85 were
also eligible for meta-analysis. The 111 studies utilized
127 datasets to produce their analyses (four studies uti-
lized two datasets, three studies utilized three datasets
and two studies utilized four datasets). No new studies
were imported through reference checking.
Of 127 identified datasets, only 2 were reported to rep-
resent a prospective cohort; of the rest, 19 were reported
to represent a retrospective cohort and there were
no relevant information for the remaining 106 datasets.
No report specified what type of population their sam-
ples came from and for 113/127 datasets we have no in-
formation as to what sampling method was used to
obtain the sample. For the remaining datasets, consecu-
tive sampling was stated to have been used in 5 and ran-
dom sampling in 4 datasets; 5 datasets were based on all
patients ever seen by the clinic. Sampling method was
disproportionately frequently reported for studies com-
ing from the USA (4/9). A total of 94/127 datasets came
from Asia (78 from China), followed by Europe (15/127)
and America (13/127); there was no reported country of
origin for 2 datasets and 3 datasets contained patients
from multiple continents; the latter were multi-center
cohorts. A total of 16,754 different patients were en-
rolled within these studies (avoiding double-counting
samples that had been used for two or more analyses).
Median sample size was 90 (IQR, 82; range, 30–997)
and 69/127 datasets contained less than 100 participants
(50 of which datasets came from China).
Mapping of lncRNA prognostic data
The eligible reports studied 18 types of cancer, top three
most studied of which were gastric cancer (n = 16 data-
sets), lung cancer (n = 15) and colorectal cancer (n = 15)
(Table 1). Almost half of the reports studied cancer re-
lated to the gastrointestinal tract (57/127 datasets). OS
was assessed in 92/111 studies (83 %), RFS in 36 (32 %),
DSS in 10 (9 %), MFS in 9 (8 %) and PFS in 6 (5 %). The
majority of studies did not appear to choose what
lncRNAs to study on the basis of agnostic reports (77 %,
85/111). For 98/127 datasets (77 %), there was no infor-
mation regarding adjuvant treatment; for the 29 studies
providing information regarding treatment, only 4 data-
sets indicated that their patients were treated homoge-
neously. In addition to survival analysis, 68 % (76/111)
of the identified studies attempted to further study their
chosen lncRNAs in vitro, to corroborate the results of
their survival analyses with mechanistic insights into the
function of their chosen lncRNAs. Across 66 studies
reporting multivariable analyses, 42 adjusted for stage of
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Fig. 1 A flow diagram demonstrating the study selection process. Out of 397 identified records, 111 were chosen for systematic review and 85
for overall survival meta-analysis. Duplicate exclusion refers to the process of asserting that each paper is only represented once within our set of
records. Initially, 111 records with titles seemingly irrelevant to the objectives of our study were excluded, following which another 81 records
were excluded after reading through the remaining 192 papers, for the reasons identified within the diagram. This process led to the identification of
111 papers eligible for systematic review. We then applied our meta-analysis eligibility criteria to these papers, on the basis of which 26 were excluded,
for the reasons identified in the diagram. This process led to the identification of 85 papers eligible for meta-analysis
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Table 1 Descriptive statistics of eligible studies
Characteristic Subgroups Frequency (%)
Year 2000–2013 13 (12 %)
2013–2014 23 (21 %)
2014–2014 0 (0 %)
2014–2015 75 (68 %)
N 111 (100 %)
Cancer site Gastric 16 (13 %)
Colorectal 15 (12 %)
Lung 15 (12 %)
Brain 12 (9 %)
Esophageal 10 (8 %)
Prostate 10 (8 %)
Hepatic 9 (7 %)
Breast 6 (5 %)
Pancreatic 6 (5 %)
Cervical 5 (4 %)
Head and neck 4 (3 %)
Ovarian 4 (3 %)
Renal 4 (3 %)
Urinary bladder 4 (3 %)
Any 2 (2 %)
Hematologic 2 (2 %)
Endometrial 1 (1 %)
GIST 1 (1 %)
Neuroblastoma 1 (1 %)
N 127 (100 %)
Agnostic a No 85 (77 %)
Yes 21 (19 %)
Agnostic parent 5 (5 %)
N 111 (100 %)
Survival analysis OS 92 (83 %)
RFS 36 (32 %)
DSS 10 (9 %)
MFS 9 (8 %)
PFS 6 (5 %)
N 111 (100 %)
Quantification method qRT-PCR 84 (66 %)
ISH 28 (22 %)
qPCR 11 (9 %)
qRT-PCR or ISH 2 (2 %)
RT-qPCR 1 (1 %)
Unreported 1 (1 %)
N 127 (100 %)
Continent Asia 94 (74 %)
Europe 15 (12 %)
Table 1 Descriptive statistics of eligible studies (Continued)
America 13 (10 %)
Multiple 3 (2 %)
Unreported 2 (2 %)
N 127 (100 %)
Study design Unreported 106 (83 %)
Retrospective 19 (15 %)
Prospective 2 (2 %)
N 127 (100 %)
Sampling method Unreported 113 (89 %)
Consecutive 5 (4 %)
Population 5 (4 %)
Random 4 (3 %)
N 127 (100 %)
Tissue preservation b L 66 (52 %)
Unreported 34 (27 %)
P 18 (14 %)
LP 6 (5 %)
L + RNALater 3 (2 %)
N 127 (100 %)
Pre-biopsy treatment No 77 (61 %)
Unreported 46 (36 %)
Yes 4 (3 %)
N 127 (100 %)
Post-biopsy treatment Unreported 98 (77 %)
Yes 27 (21 %)
No 2 (2 %)
N 127 (100 %)
Total number of lncRNAs
studied
1 87 (78 %)
2–10 4 (4 %)
11–45033 15 (14 %)
Unreported 5 (5 %)
N 111 (100 %)
Outcomes Clinical and Non-clinical 76 (68 %)
Clinical only 35 (32 %)
N 111 (100 %)
Use of validation method
for survival
Unreported 99 (89 %)
External 5 (5 %)
Internal 4 (4 %)
Both 2 (2 %)
Yes 1 (1 %)
N 111 (100 %)
These data are based on 111 studies of 127 datasets. N refers to the total
number of observations for each characteristic
a Agnostic studies are those in which no prior knowledge is assumed
regarding the choice of lncRNA to be studied
b Tissue preservation: L (liquid nitrogen), P (paraffin-embedded), LP (liquid
nitrogen and/or paraffin-embedded
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Fig. 2 (See legend on next page.)
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cancer (or all three components of the TNM staging)
and 27 for grade of cancer; only 19/66 studies ad-
justed for both. Figure 2 displays a microarray of the
covariates that have been studied more than three
times within multivariable analyses (Additional file 3:
Figure S1 displays the complete data microarray).
Out of all 66 studies, 20 (30 %) studies adjusted for
the same factors as at least one other paper and the
most commonly encountered combination of fac-
tors adjusted for was Stage and Lymph Node Metas-
tasis, which was seen in 6/66 studies. The median
number of adjustment combinations matching be-
tween at least two papers was 1 (IQR, 0).
Overall survival
Out of 92 studies reporting on OS, 87 studies (repre-
senting 111/127 analyses, as explained in Additional file
4: Table S1) provided effect estimates, out of which two
were completely excluded due to reporting inconsistent
effect sizes, as indicated in the Methods [35, 37]. The 85
remaining studies provided effect estimates on 53
lncRNAs and 6 multi-lncRNA risk score scales. The
three most frequently studied lncRNAs within OS ana-
lyses were HOTAIR (n = 29 effect estimates), MALAT1
(n = 8) and GAS 5, H19 and PVT1 (n = 4 for each). Most
individual lncRNAs (42/53) were only studied once
(Table 2). Only 7 lncRNAs were studied at least three
times in association to OS and for 6 of them more than
half of the studies showed statistically significant p-values.
These lncRNAs were studied in the context of a median
of 4 different types of cancer (IQR, 3). Out of the 52 indi-
vidual or groups of lncRNAs studied less than three times,
44 were always reported significantly associated to OS.
Overall, of the 92 studies reporting on OS (but not neces-
sarily quoting an effect estimate), 88 (96 %) reported at
least one statistically significant result for association with
prognosis.
Meta-analysis for overall survival
A meta-analysis of OS was done for all 7 individual or
groups of lncRNAs having been studied three or more
times (Fig. 3; Table 3; Additional file 1: Table S2). For
p-value < 0.0005, 5 lncRNAs were statistically signifi-
cantly associated to OS in all of our meta-analyses
(See figure on previous page.)
Fig. 2 The covariates used within the multivariable models fitted by each paper. This is a data microarray in which the studies run along the
Y-axis and the covariates run along the X-axis. Only the factors used three or more times are shown in this figure for convenience; refer to
Additional file 3: Figure S1 for a data microarray illustrating all covariates studied. Rows and columns are ordered in descending order, based on
how many times each covariate was included in the multivariable models fitted by each study. Where patterns were similar between studies or
covariates, those papers or covariates were placed next to each other. It is evident that very few studies included the same covariates within their
models and that less than half of the studies included both Stage and Grade within those models. Interestingly, according to Additional file 3: Figure S1,
the majority of studies included at least one covariate within their model that had not been included in any other study. Green = Included in the
multivariable model; Red = Not included in the multivariable model. LNM = Lymph node metastasis; T = Depth of invasion; M = Metastasis;
KPS score = Karnofsky Performance Status score (a measure of functional impairment); LVM = Lymphovascular metastasis










HOTAIR 29 13 (3886) 100 (69) 28 (97 %)
MALAT1 8 7 (1135) 136 (53) 5 (62 %)
H19 4 2 (440) 77 (57) 2 (50 %)
PVT1 4 4 (420) 87 (24) 4 (100 %)
GAS5 4 4 (369) 96 (19) 4 (100 %)
SChLAP1 3 1 (1396) 357 (440) 3 (100 %)
6 lncRNA risk
score
3 1 (281) 42 (94) 1 (33 %)
CCAT2 2 2 (1226) 613 (384) 1 (50 %)
LncR1 vs LncR2 vs
LncR3
2 1 (759) 380 (96) 2 (100 %)
ENSG00000261582 2 2 (576) 288 (199) 2 (100 %)
MVIH 2 2 (257) 128 (86) 2 (100 %)
LOC285194 2 2 (227) 114 (28) 2 (100 %)
PCAT1 2 2 (212) 106 (2) 2 (100 %)
SPRY4-IT1 2 2 (190) 95 (3) 2 (100 %)
UCA1 2 2 (170) 85 (5) 2 (100 %)
GHET1 2 2 (122) 61 (19) 2 (100 %)
MEG3 2 2 (116) 58 (14) 2 (100 %)
The following lncRNAs were studied once and found statistically significant:
LINC00968, LINC01234, LINC00476, FLG-AS1, HOTTIP, TC0101686, TC0100223.
The following lncRNAs were studied once and were not found significant: linc-
UBC1, KIAA0495, PART1, MGC21881, MIAT, PAR5, ADAMTS9-AS2, BCAR4,
XLOC_010588, FOXCUT, 3 lncRNA risk score, FENDRR, HIF1A-AS2, ANRIL, GAPLINC,
MRUL, HEIH, HOXA13, 48 lncRNA risk score, BANCR, ZXF1, CARLo-5, GAS6-AS1,
Sox2ot, TUG1, NAG7 - LINC00312, CAI2, TC0101441, ENST00000480739,
BC008363, 80-gene SChLAP1 signature risk score, 167-gene SChLAP1 signature
risk score, CADM1-AS1, RCCRT1, CCAT1. Significance in the table refers to p-value
< 0.05, as this is what had been used by these studies
The ‘Times studied’ column refers to how many studies investigated each
lncRNA. The ‘Number of cancer types’ column indicates in how many different
cancer types each lncRNA was studied, with the total number of participants
used to study each lncRNA in brackets. The ‘Median’ column indicates the
median sample size for each cohort used to study each lncRNA, with the
interquartile range (IQR) in brackets. The last column indicates how many
times each lncRNA was found to be statistically significantly associated to
prognosis and in brackets the relation of how many times it was found to be
significant versus how many times it was studied
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Fig. 3 Forest plots for OS meta-analyses. We hereby illustrate the lncRNAs for which three or more studies reported OS. Each panel a-g corresponds to
the meta-analysis of a different lncRNA: (a) HOTAIR, (b) MALAT1, (c) PVT1, (d) 6 lncRNA risk score, (e) SChLAP1, (f) H19 and (g) GAS5. The effect size for
the estimate of each study is presented as a blue square proportional in size to the weight of that study. The confidence interval around that effect size
is presented as a horizontal line. Where the confidence interval exceeds the range of our plot, an arrow has been placed. The vertical line across these
estimates represents HR = 1 and any horizontal line crossing this vertical line represents a non-statistically significant result. The summary effect size is
presented as a rhombus, the center of which represents the summary effect size and the width of which represents its confidence interval. It is evident
that almost all studies quoted statistically significant results and that according to the available data, all meta-analyzed lncRNAs, apart from
GAS5 (panel g), are statistically significantly associated to prognosis of OS in cancer. However, high between-study heterogeneity (based on the
range of I2 estimates) indicates that these summary effect sizes are unreliable
Table 3 The results of our meta-analysis for each lncRNA using ‘primarily multivariable’ data
LncRNA Studies HR (95 % CI) P-value I2 (95 % CI) Observed (Expected, p-value)
HOTAIR 26 2.22 (1.86–2.65) 0.0000 49 % (14–79 %) 25 (18.2, p-value = 0.002)
MALAT1 7 2.03 (1.64–2.52) 0.0000 0 % (0–85 %) 5 (4.1, p-value = 0.707)
6 lncRNA risk score 4 1.57 (1.29–1.92) 0.0000 0 % (0–47 %) 2 (2.1, p-value = 1.000)
GAS5 4 0.81 (0.33–2.00) 0.6479 94 % (80–100 %) 4 (2.1, p-value = 0.128)
H19 4 1.16 (1.04–1.29) 0.0100 0 % (0–98 %) 2 (0.8, p-value = 0.170)
PVT1 4 2.99 (2.10–4.27) 0.0000 0 % (0–56 %) 4 (2.7, p-value = 0.309)
SChLAP1 3 1.98 (1.55–2.54) 0.0000 0 % (0–98 %) 3 (2.9, p-value = 1.000)
‘Studies’ refers to the number of studies included in the meta-analysis of each lncRNA. HR = Hazard Ratio, 95 % CI = 95 % Confidence Interval. I2 is a measure of
between-study heterogeneity. The last column refers to how many statistically significant results had been reported by the included studies (Observed, O), how
many were expected to be reported on the basis of each study’s power (Expected, E) and whether O and E are statistically significantly different from each other
for each meta-analysis (p-value). Please refer to Additional file 1: Table S2 for a table illustrating all meta-analyses done (not only the one for primarily multivariable
data) with all of the measures calculated
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(HOTAIR, MALAT1, 6 lncRNA risk score, PVT1,
SChLAP1) and 6/7 were statistically significant in all of
our meta-analyses at p-value < 0.05 (H19; Additional
file 1: Table S2). An increase in cellular expression of
these lncRNAs was statistically significantly associated
to a decrease in overall survival; GAS5 was not statisti-
cally significantly associated to OS in our meta-
analyses. The funnel plot for HOTAIR (Fig. 4), which is
the only lncRNA studied 10 or more times, indicates
significant small-study effects (p-value = 0.0006), and
this may be suggestive of publication bias. The sum-
mary effect size for HOTAIR also displays a moderate
amount of between-study heterogeneity (I2, 48 %; 95 %
CI, 14–78 %). The summary effects for the effect of
HOTAIR on OS in cancers for which it was studied 3
or more times were: colorectal cancer (HR, 4.76; 95 %
CI, 2.46–9.21), esophageal cancer (HR, 2.29; 95 % CI,
1.68–3.12) and glioma (HR, 1.71; 95 % CI, 1.25–2.34).
Other meta-analyses
The only type of survival analysis other than OS studied
3 or more times in relation to a specific lncRNA was
MFS for HOTAIR. This was investigated within 4 differ-
ent studies in relation to 4 different cancers (breast,
colorectal, esophageal, head and neck). Meta-analysis of
these studies identified a summary HR of 2.54 (95 % CI,
1.62–3.98) with no statistically significant heterogeneity
(Q-statistic, 5.16; p-value = 0.16).
Heterogeneity metrics and excess significance
Statistically significant heterogeneity was only observed
in HOTAIR analyses, but substantial estimates of I2 were
common. For HOTAIR and OS, a sensitivity analysis ex-
cluding the only study reporting an inverse correlation
of HOTAIR to cancer survival [33] generated a HR of 2.30
(95 % CI, 1.97-2.70) with I2 = 0 % (95 % CI, 0–59 %); for
all other meta-analyses, no single study produced a major
change in the I2.
There was excess significance across the whole field for
overall survival and the binomial distribution revealed a
two-tailed p-value of 0.0003, with O = 42 statistically sig-
nificant results and E = 30 expected statistically significant
results across all meta-analyses with 3 or more studies
each on OS. As far as excess significance within
lncRNAs studied 5 or more times is concerned, there
was significant excess significance documented for
HOTAIR (p-value = 0.002), but not MALAT1 (p-value
= 0.46).
Discussion
In this systematic review and meta-analysis we have tried
to gather all published papers evaluating the prognostic
ability of lncRNAs in cancer. We have identified that a
large number of lncRNAs have been evaluated within
the context of cancer prognosis. Most of them have been
evaluated only once in a published paper. Almost all of
the published papers report that lncRNAs are statisti-
cally significant predictors of survival. There was often
substantial heterogeneity between studies in the strength
of the predictive effect. There was also strong evidence
for small-study effects and for excess significance. This
picture may be due to genuine differences across studies,
such as different cancers and populations under study,
and different adjustments made in multivariable models.
However, it is also highly compatible with the presence
of substantial publication bias and other selective report-
ing bias in this field resulting in exaggerated effects in
mostly small studies (most of which coming from China)
and in an implausibly high prevalence of nominally sig-
nificant results.
It is well recognized that published literature on prog-
nosis and the identification of prognostic markers is
characterized by poor methodological quality, significant
publication bias and wide heterogeneity in aspects of
sample selection, such as pre/post-biopsy treatment or
tissue preservation methods, and analysis, such as multi-
variable modelling and determination of cutoff values
[30, 46]. As such, meta-analyses of prognostic studies
may elicit summary effect sizes that are unrealistic [47].
An evaluation of studies investigating the association of
TP53 to risk of death by head and neck squamous cell
carcinoma, identified that even though readily available
effect sizes would confirm that TP53 is a strongly
























0.10 0.25 0.50 1.00 2.00 5.00 15.00 40.00
HOTAIR
Fig. 4 Funnel plot for the OS meta-analysis of HOTAIR. The
meta-analysis for HOTAIR was analyzed with a funnel plot because it
exceeded the pre-requisite of 10 studies. The Y-axis represents the
Standard Error (SE), which serves as a measure of precision, where the
higher the SE, the less precise the study. The HR has been plotted
along the X-axis. The black dots map the effect size of HOTAIR on OS
as this has been identified by each study. The light grey and dark grey
areas respectively denote the 95 % and 99 % CI around the summary
effect size. According to this plot, it is clear that the least precise studies
tend to overestimate the effect size of HOTAIR on OS, skewing the
summary effect size to the right (i.e. leading to a more strongly positive
summary effect size)
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significant prognostic factor, after standardizing definitions
of TP53 status and outcomes across papers and retrieving
non-readily available information, this association was
completely abrogated [48]. These issues may also apply to
the lncRNA literature. No two studies of our dataset were
identical in all of lncRNA, cancer site, cut-off value and
multivariable modelling, suggesting substantial room for
selective reporting of analyses that could be done with very
different models and definitions. Moreover, we suspect that
publication bias may also be operating in the field.
Of particular interest is the excess significance we
identified across the field (p-value = 0.0003). Despite the
poor translation of cancer biomarkers into clinical prac-
tice [39, 49–51], out of 1575 studies on cancer bio-
markers published in 2005, 95.8 % reported statistically
significant results and only 1.3 % did not report any kind
of statistically significant results [52]. Indeed, as we have
shown, this pattern is also prominent in the lncRNA
cancer prognosis literature.
One way of reducing the selective reporting biases that
have led to the above status quo and thus reducing lack
of translatability, is transparency. The need to improve
transparency has been mentioned repeatedly [39, 53].
Guidelines have been proposed to improve the reporting
of prognostic markers (REMARK) [39, 51], multivariable
prediction models (TRIPOD) [54] and genetic risk pre-
diction studies [55]. Wider adoption of these guidelines
may increase transparency, but it is unknown whether it
will suffice to markedly reduce selective reporting.
In our cohort of studies, the extent of unreported
items in Table 1, did not inspire confidence in transpar-
ency and completeness of reporting practices. We also
documented minimal use of validation (12/111 studies,
11 %), despite reports stressing the necessity and import-
ance of validation in identifying true effect size for prog-
nostic tools [56, 57]. Furthermore, more than half of the
identified studies had a sample size of less than 100.
Small studies are known, both theoretically and empiric-
ally, to be associated with inflated estimates of effect size
[58], not as much due to their limited sample size, as for
lower quality standards, publication bias and selective
reporting [59], which is why they lead to so-called
‘small-study effects’. Even though these have mostly been
studied within the context of randomized-controlled tri-
als, where they have been associated with a larger aver-
age effect size and at least double the between-study
heterogeneity found in larger studies [60], similar prob-
lems may occur also in prognostic study research [43].
The meta-analysis for HOTAIR, which is the most
widely studied lncRNA in the context of cancer progno-
sis, clearly indicates that smaller studies tend to be less
precise and report a higher effect size than larger stud-
ies. Inflated effects are common in biomarker studies
[61], and this may apply also for the results of lncRNAs.
Another interesting point of note is the Chinese prov-
enance of most papers in our collection of eligible stud-
ies (78/111, 70 %). In a previous analysis of genetic
studies, it was shown that there is a vast Chinese litera-
ture, and that papers from China tend to utilize smaller
sample sizes yet reach statistical significance far more
commonly than other papers [62]. This was attributed to
more prominent publication bias against null results or
other kinds of selection bias in pursuit of statistically
significant results. Discrepancies between the Chinese
literature and the rest of the world were also found in
published meta-analyses of genomic data [63]. Chinese
meta-analyses (1) focused on the results of studies inves-
tigating individual candidate genes rather than the re-
sults of genome-wide association studies and (2) used
nominal significance (i.e. p-value < 0.05) rather than
genome-wide p-value thresholds to identify statistically
significant results.
Although there has been an explosion in the amount
of identified potential biomarkers due to high through-
put methods, unlike traditional methods of identifying
molecules directly relevant to a known cellular event
[49], very few have made their way to clinical practice, due
to lack of appropriate evidence [50, 64, 65]. An important
aspect in ascribing usefulness to a novel biomarker is their
ability to add further predictive value, over and above the
one already possible using known prognostic factors.
Unfortunately, in our sample, despite most multivariable
analyses identifying lncRNAs as a statistically significant
predictor, only about 30 % of the reported prognostic
effects were adjusted for the two classically most relevant
predictors of cancer prognosis (i.e. Stage and Grade).
Limitations
Our analysis has several limitations. First, given that this
report is only based on the results of a single database
(PubMed), it is possible that relevant papers may have
been missed. Second, our analysis utilized the Medical
Subject Heading (MeSH) ‘Humans’ to limit our search
results to those studies conducted in humans. Even
though this is accepted practice and has been used pre-
viously in similar studies [5], that label is added to pa-
pers at the point of indexing, and thus some papers that
were published close to our search date (September 26,
2015) and had not been MeSH-labeled yet, would have
been missed. We performed an updated search (June 5,
2016) for papers that did not have a Human [MeSH]
and had been published before 2015 and found only two
small studies [66, 67] that could potentially qualify for
inclusion for the outcome of survival. This is a field with
prolific literature and a substantial number of papers
have continued to appear after our September 2015
search and will probably continue to appear in the near
future. Third, our meta-analysis has attempted to combine
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multiple studies that are known to be heterogeneous in
terms of cancer site and provenance of patient popula-
tions. Our estimates of heterogeneity metrics have wide
95 % confidence intervals [42]. Fourth, on 51 occasions
we had to calculate HRs ourselves based on data provided
within the papers, which may not have provided the most
accurate estimate of the HR possible, as most of the time
these data were extracted from Kaplan-Meier curves.
However, this practice has not been shown to yield results
significantly different from direct methods of HR estima-
tion [29]. Fifth, even though every effort was made to ex-
clude analyses of the same lncRNA using the same dataset
of patients, it is possible that some overlapping data have
been included, if their authors have made no hint as to
the presence of overlap.
Conclusions
In conclusion, we have gathered a substantial amount of
prognostic data regarding the association of various
lncRNAs and survival. Our analysis identified a signifi-
cant number of studies, most of which have been pub-
lished within the last 2 years and most of which are of
small sample size. Even though our systematic review
and meta-analyses identified that almost all lncRNAs
identified are statistically significant predictors of OS, it
is very difficult to know the importance of these associa-
tions, given the detection of excess significance, small-
study effects and the known difficulties with analyzing
prognostic studies. Larger studies, ideally with collab-
orative teams using standardized approaches to meas-
urement, adjustment, analysis, and reporting, will offer
better insights into the prognostic value of lncRNAs.
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